Molecular mechanisms of left atrial fibrosis development in patients with atrial fibrillation and metabolic syndrome: what biomarkers should be used in clinical practice?
Aim. To determine the blood concentration of fibrosis biomarkers in patients with atrial fibrillation (AF) in combination with metabolic syndrome (MS) and to analyze the relationship with myocardial fibrosis.Material and methods. This cross-sectional case-control study included 547 patients aged 35...
Saved in:
| Main Authors: | V. A. Ionin, E L Zaslavskaya, E I Barashkova, V A Pavlova, G I Borisov, K A Averchenko, A N Morozov, E I Baranova, E V Schlyachto |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2021-08-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4579 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
What is the role of profibrogenic and proinflammatory factors in developing atrial fibrillation associated with metabolic syndrome components?
by: V. A. Ionin, et al.
Published: (2021-12-01) -
Fibrosis biomarkers as predictors of left atrial appendage thrombosis in patients with nonvalvular atrial fibrillation
by: T. P. Gizatulina, et al.
Published: (2022-08-01) -
GALECTIN 3 AND ALDOSTERONE IN PATIENTS WITH ATRIAL FIBRILLATION AND METABOLIC SYNDROME
by: V. A. lonin, et al.
Published: (2015-04-01) -
The role of fibrosis biomarkers in predicting the development of myocardial electrical instability (a literature review)
by: V. P. Ivanov, et al.
Published: (2021-04-01) -
Biomarkers of fibrosis and inflammation and the risk of arrhythmia recurrence after elective electrical cardioversion in patients with atrial fibrillation and metabolic syndrome
by: E. I. Barashkova, et al.
Published: (2024-06-01)